Status:
COMPLETED
Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
35+ years
Phase:
PHASE4
Brief Summary
This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Insulin glargine versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in combination with ...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Body mass index equal to or lesser than 35.0 kg/m2
- Currently treated with oral hypoglycaemic drug
Exclusion
- Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator
- Any condition that the Investigator and/or the Sponsor feel would interfere with trial participation or evaluation of results
Key Trial Info
Start Date :
September 10 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 24 2005
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT00184626
Start Date
September 10 2004
End Date
October 24 2005
Last Update
February 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Istanbul, Turkey (Türkiye), 111